Mark your calendars! REPRIEVE will be hosting two Community Forums to review the trial results. These will be held on Thursday, September 21st at 1:00 PM ET (English) and Friday, September 29th at 11:00 AM ET (Spanish). Join the forums using the Zoom links below!
¡Marquen sus calendarios! REPRIEVE organizará dos Foros Comunitarios para revisar los resultados de las pruebas. Estos se llevarán a cabo el jueves 21 de septiembre a la 1:00 PM ET (inglés) y el viernes 29 de septiembre a las 11:00 AM ET (español). ¡Únete a los foros usando los enlaces de zoom a continuación!
About REPRIEVE: People living with HIV are at risk of developing cardiovascular disease. To determine whether a statin medication (pitavastatin) would reduce major adverse cardiovascular events (for example, heart attacks and strokes) in PWH, the Randomized Trial to Prevent Vascular Events (REPRIEVE) enrolled a representative global sample of PWH for whom statin treatment is not typically recommended under current guidelines. The goal of the study was to find out if pitavastatin reduced major adverse cardiovascular events. REPRIEVE was stopped early, after about an average of 5 years of follow-up, after demonstrating a clear effect of pitavastatin (vs. placebo) to prevent major adverse cardiovascular events. Please join us for a Community Forum during which the primary findings from REPRIEVE will be shared, and the meaning of the results for people living with HIV will be discussed to better understand how they might influence guidelines for the care of PWH.
If you were unable to join these forums, check back here for slides and a recording of each presentation!